Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Accenture
Express Scripts
Moodys
Federal Trade Commission
Cerilliant
Cantor Fitzgerald
Healthtrust
McKinsey
QuintilesIMS

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,226,614

« Back to Dashboard

Summary for Patent: 7,226,614
Title:Tablet comprising cetirizine and pseudoephedrine
Abstract:The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.
Inventor(s): Fanara; Domenico (Wanze, BE), Guichaux; Anthony (Fribourg, CH), Berwaer; Monique (Ham-sur-Heure-Nalinnes, BE), Deleers; Michel (Linkebeek, BE)
Assignee: UCB Farchim SA (Bulle, CH)
Application Number:11/251,895
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,226,614

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
J And J Consumer Inc ZYRTEC-D 12 HOUR cetirizine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 021150-002 Nov 9, 2007 OTC Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,226,614

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01115807Jun 28, 2001

Non-Orange Book US Patents Family Members for Patent 7,226,614

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,014,867 Tablet comprising cetirizine and pseudoephedrine ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,226,614

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034866 ➤ Subscribe
Austria 432068 ➤ Subscribe
Australia 2002345024 ➤ Subscribe
Bulgaria 108452 ➤ Subscribe
Bulgaria 66269 ➤ Subscribe
Brazil 0210650 ➤ Subscribe
Canada 2451519 ➤ Subscribe
China 100490809 ➤ Subscribe
China 1520285 ➤ Subscribe
Colombia 5540370 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Farmers Insurance
Deloitte
Dow
Cantor Fitzgerald
Johnson and Johnson
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot